

Frederick William Miller, M.D., Ph.D.

Curriculum Vitae, November 2008

PERSONAL INFORMATION

Business Address Chief, Environmental Autoimmunity Group
Office of Clinical Research
National Institutes of Environmental Health Sciences (NIEHS)
National Institutes of Health, DHHS
Clinical Research Center, Rm. 4-2352
10 Center Drive, MSC 1301
Bethesda, MD 20892-1301

Phone: 301-451-6273
Fax: 301-451-5585
Email: millerf@mail.nih.gov
Website: <http://www.niehs.nih.gov/research/clinical/program/groups/eagroup.cfm>

Home Address 3518 Astoria Court
Kensington, MD 20895-1434

Date of Birth January 25, 1951

Birthplace Troy, OH

Citizenship United States

MAJOR RESEARCH INTERESTS

Genetic and Environmental Risk Factors and Pathogenesis of Immune-mediated Diseases
Outcome Assessment and Therapy of Autoimmune Disorders

EDUCATION

1979 M.D., Ph.D., Medical Scientist Training Program, Department of Anatomy and Developmental Biology Center, Case Western Reserve University School of Medicine, Cleveland, OH

1973 B.A., Zoology, with minor in Chemistry, *Summa cum laude*, General Honors, Miami University, Oxford, OH

1969 Salutatorian, Troy High School, Troy, OH

PROFESSIONAL EXPERIENCE

- Since 2001 Chief, Environmental Autoimmunity Group, Office of Clinical Research, DIR, NIEHS, NIH, Bethesda, MD, Tenured Senior Investigator, Captain, US Public Health Service, Research Officer Group.
- 11/96-2000 Senior Investigator and Medical Officer – Clinical and Product Reviewer, Laboratory of Molecular and Developmental Immunology, Division of Monoclonal Antibodies, CBER, FDA, Bethesda, MD.
- 10/93-10/96 Senior Investigator and Medical Officer – Clinical and Product Reviewer, Molecular Immunology Laboratory, Division of Cellular and Gene Therapies, CBER, FDA; Tenured Senior Investigator, US Public Health Service Research Officer Group 1994.
- 12/90-9/93 Senior Investigator and Medical Officer - Clinical and Product Reviewer, Division of Biochemistry and Biophysics, CBER, FDA, Bethesda, MD.
- 8/86-11/90 Senior Staff Fellow and Clinical Associate - Arthritis and Rheumatism Branch, NIAMS, NIH, Bethesda, MD.
- 7/83-7/86 Medical Staff Fellow (Rheumatology Fellowship) - Arthritis and Rheumatism Branch, NIAMS, NIH, Bethesda, MD.
- 7/81-6/83 Medical Resident - Department of Medicine, Stanford University Medical Center, Stanford, CA.
- 7/80-6/81 Clinical Research Fellow - Clinical Research Facility, Emory University Medical Center, Atlanta, GA.
- 7/79-6/80 Medical Intern - Department of Medicine, Emory University School of Medicine Affiliated Hospitals, Atlanta, GA.

BOARD CERTIFICATIONS

- Subspecialty Certification in Rheumatology (10/1990 and 10/2000)
 American Board of Internal Medicine (10/83)
 National Board of Medical Examiners (7/80)

MEDICAL LICENSURE

- | | | |
|------------|---------|-------------------|
| Maryland | #D30329 | (9/83) |
| California | #45861 | (10/81, inactive) |

SELECTED PROFESSIONAL SOCIETIES

Fellow, American College of Physicians
 Fellow, American College of Rheumatology
 Member, American Association of Immunologists
 Member, International Myopain Society
 Member, Henry Kunkel Society
 Member, District of Columbia Rheumatism Society

SELECTED PROFESSIONAL HONORS AND RECOGNITION

2007 Hero Award, The Cure Juvenile Myositis Foundation, for “Dedication to Finding a Cure for Juvenile Myositis”
 2005 The Dunlop-Dotteridge Lectureship, Canadian Rheumatology Assoc., Mt. Tremblant
 2005 NIH Merit Award for participation on the NIEHS Strategic Planning Workgroup
 2003 The Kovacs Lectureship, the Royal Society of Medicine, London
 2000 Elected member of the Henry Kunkel Society
 2000 Elected to Best Doctors in America
 1999 US Public Health Service Meritorious Service Medal
 1999 US Public Health Service Outstanding Unit Citation
 1998 US Public Health Service National Vaccine Program Award
 1998 US Public Health Service Unit Commendation Medal
 1997 FDA Office of Woman's Health Grant recipient
 1994 Elected Fellow, American College of Rheumatology
 1992 FDA Office of Woman's Health Grant recipient
 1989 William R. Felts Award for Excellence in Rheumatology Research
 1986 American College of Rheumatology Senior Fellow Research Award
 1985 Elected Fellow, American College of Physicians
 1979 Hughes Research Award, Case Western Reserve University
 1974-1977 National Research Service Awards, Case Western Reserve University
 1973 Selected as NIH Trainee - Fertilization & Gamete Physiology Training Program, Marine Biology Laboratory, Woods Hole, MA
 1973 B.A., *Summa cum laude*, General Honors, Miami University
 1973 Elected to Phi Beta Kappa Honor Society, Miami University
 1973 Hughes Chemistry Award, Miami University
 1972 Culler Physics Award, Miami University
 1971 Elected to Phi Beta Sigma Honor Society, Miami University
 1971-1972 Alan Brewer Memorial Scholarships, Miami University
 1969-1970 John Rawlings Memorial Scholarships, Miami University

MENTORSHIP ACTIVITIES

Directed research and mentored dozens of undergraduate students, graduate students, medical students, postdoctoral fellows, clinical research fellows, visiting scientists, guest workers and summer students at the Food and Drug Administration and National Institutes of Health from 1983-present.

SELECTED SCIENTIFIC LEADERSHIP AND COMMITTEE WORK

NIH, FDA and other Federal Agencies

Chair, NIEHS Clinical Center Utilization Review Committee, 2008-present
 Member, NIH Translational Research Interest Group Steering Committee, 2008-present
 Member, NIH Center for Human Immunology Planning Committee, 2007-present
 Member, Trans-NIH Bioethics Committee, 2005-present
 Member, NIEHS Strategic Planning Forum Steering Committee, 2005-2006
 Member, NIH Roadmap Clinical and Translational Sciences Working Group, 2005-present
 Member, NIH Roadmap Translational Core Working Group, 2003-present
 Member, NIH Roadmap Regional Translational Research Center Working Group, 2003-2005
 Member, NIH Chronic Graft-Versus-Host Disease Response Criteria Working Group, 2003-present
 Member, NIH Quality Review Committee, 2004-present
 Member, NIEHS Search Committee, Staff Clinician, Clinical Research Unit, 2006
 Member, NIEHS Search Committee, Tenure-Track Clinical Investigator in host defense, 2005
 Member, NIEHS Search Committee, Tenure-Track Clinical Investigator in Gynecology, 2003
 Member, NIEHS Search Committee, Staff Clinician, Environmental Autoimmunity Group, 2002
 Alternate Member, NIH Medical Executive Committee, 2001-present
 Principal Investigator, the NIEHS Rituximab in Myositis Trial, 2006-present
 Principal Investigator, the NIEHS Natural History of Autoimmune Diseases Study, 2005-present
 Principal Investigator, the NIEHS Twin-siblings Systemic Autoimmunity Study, 2003-present
 Principal Investigator, the FDA Silicone associated Connective Tissue Disease Study, 1995-2003
 Principal Investigator, the FDA Natural History of Autoimmune Diseases Study, 1993-2005
 Principal Investigator, the FDA Myositis Developing after Vaccination Study, 1993-2005
 Principal Investigator, the FDA Myositis Developing after Silicone Implants Study, 1993-2003
 Principal Investigator, the NIAMS High Dose Methotrexate in Myositis Study, 1987- 1997
 Principal Investigator, the NIAMS Apheresis in Myositis Trial, 1986-1990
 Principal Investigator, the NIAMS Cyclophosphamide in Myositis Trial, 1986-1989
 Principal Investigator, the FDA Myositis Developing after Vaccination Study, 1993-2005
 Principal Investigator, the FDA Familial Myositis Study, 1999-2002
 Principal Investigator, the FDA Myositis Developing after Silicone Implants Study, 1993-2003
 Principal Investigator, the FDA Myeloma and MGUS following Silicone Implants Study, 1993-2003
 Associate Investigator, the NIEHS Natural History of Adult and Juvenile Myositis Study, 2001-present
 Associate Investigator, the NIAMS Infliximab in Myositis Study, 1999-present
 Associate Investigator, the NIAMS Natural History of Myositis Study, 1985-present
 Associate Investigator, the NIAMS Familial Autoimmunity Study, 1988-1993
 Associate Investigator, the NIDR Soft Tissue Calcification Study, 2002-present
 Associate Investigator, the FDA Rheumatoid Arthritis after Lyme Vaccine Study, 2001-2005
 Member, FDA Rheumatology Working Group, 1994-2002
 Member, FDA Vascular Injury Expert Working Group, 2000-2004
 Member, DHHS Silicone Breast Implant Research Task Force, 1992-1999
 Member, Armed Forces Institute of Pathology Scientific Advisory Board, Washington, DC, 1996-2000
 Member, DHHS Interagency Temporal Mandibular Disorder Working Group, 1997-2002
 Reviewer, Veterans Administration Research Merit Review Board, 1999-2002
 Member, IRB Committee, Walter Reed Army Medical Center, Washington DC, 1994-1998
 Medical Staff Guest Worker, Principal Clinical Investigator, NIH Clinical Center, Arthritis and Rheumatism Branch, NIAMS, 1990-2000

Elected representative, Committee to Advance CBER Science, FDA, 1996-2000
 Clinical IND and BLA Reviewer, Division of Clinical Trials, CBER, FDA, 1994-2002
 Product IND and BLA Reviewer, Division of Cell and Gene Therapy and Div. of Monoclonal Antibodies, CBER, FDA, 1990-2002
 Chair, FDA Biologics Licensing Application Committee, Simulect™, 1997-1998
 Chair, FDA Electronic IND (eIND) Working Group, 1995-1999
 Chair, FDA Gene Therapy Information Network Working Group, 1993-1995
 Chair, Rheumatology Focus Group, Division of Clinical Trials, CBER, FDA, 1992-1995
 Member, FDA IND Communications Working Group, 1996-1998
 Project leader and author, FDA Guidance to Industry regarding the pilot eIND Program, 1993-1999
 Project member and co-author, FDA Guidance to Industry regarding developing therapies for rheumatoid arthritis, 1998
 Project member and contributing author, FDA Guidance to Industry regarding electronic submissions of patient case report forms and case report tabulations, 1997
 Member, FDA FiRST Initiative, 1996-2000
 Advisor, FDA Office of the Commissioner and FDA Centers on regulatory issues relating to autoimmunity and genetic risk factors for adverse events, 1990-2002

Nationally and Internationally

Co-founder and Co-director, The PANLAR Myositis Consortium, 2007-present
 Founder and Director, The International Myositis Genetics Consortium (MYOGEN), 2006-present
 Category Chair, ACR National Meeting Abstract Selection Committee, 2005-2006
 Co-organizer and Member, Steering Committee, ACR-EULAR International Myositis Classification Criteria Project, 2003-present
 Founder and Director, the Environmental Myositis Collaborative Study Group, 2000-present
 Co-founder and Co-Director, The International Myositis Assessment and Clinical Studies Group (IMACS), 2000-present
 Co-founder, the Childhood Myositis Heterogeneity Collaborative Study Group 1995-present
 Co-founder, the Childhood Myositis Disease Activity Collaborative Study Group, 1995-present
 Member, Research Review Committee, The NIAMS Rituximab in Myositis Trial, 2004-present
 Member, Steering Committee, The NIAMS Rituximab in Myositis Trial, 2002-present
 Member, Nominations Committee, The Myositis Association, 2007-present
 Member, Medical Advisory Board, The Myositis Association, 2000-2008
 Member, Board of Directors and Medical Advisory Board Vice-Chair, The Myositis Association, 2000-2004
 Invited presenter, NAS Institute of Medicine Silicone Scientific Review Committee, 1998
 Member, OMERACT Toxicity Assessment Task Force, 1996-2003
 Founder and Chair, American College of Rheumatology Environmentally-Associated Rheumatic Diseases Study Group, 1994-99
 Member, ACR National Meeting Myositis Abstract Selection Committee, 1990, 1991, 1992, 1996, 1997, 1998-2001, 2004-2007
 Member, Juvenile Dermatomyositis Registry Advisory Board, 1996-2003
 Selected presenter, American College of Rheumatology Meet the Expert Series, Myositis and Myopathies, 1996-1998 and 2001-2003
 Board Member/Advisor, the National Dermatomyositis Support Group, 1994-1996
 Founder and Director, the International Myositis Collaborative Study Group, 1993-present

SELECTED ORGANIZATION OF WORKSHOPS, SYMPOSIA, CONFERENCES

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies Meeting, San Francisco, CA, October 27, 2008

Organizer and moderator, The International Myositis Genetics Consortium (MYOGEN) annual meeting, Boston, MA, November 9, 2007

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies Meeting, Boston, MA, November 10, 2007

Organizer and moderator, The International Myositis Genetics Consortium (MYOGEN) organizational meeting, Washington, DC, November 13, 2006

Co-organizer and speaker, The International Myositis Assessment and Clinical Studies Meeting, *Update on Myositis Clinical Studies*, Washington, DC, November 14, 2006

Co-organizer and co-moderator, The PANLAR Myositis Consortium, Organizational meeting, Lima, Peru August 21, 2006

Co-organizer and moderator, The International Myositis Assessment and Clinical Studies Meeting, *Update on Myositis Clinical Studies and the IMACS Data Repository*, San Diego, CA, November 13, 2005

Co-organizer and moderator, *The ACR-EULAR International Myositis Classification Criteria Project Working Group Workshop*, Dulles, VA, November 10-11, 2005

Organizer and moderator, *The ACR-EULAR International Myositis Classification Criteria Project Steering Group Workshop*, Bethesda, MD, October 26, 2004

Co-organizer, 3rd International Myositis Assessment and Clinical Studies Workshop, *Planning for Myositis Clinical Studies and the IMACS Data Repository*, Orlando, FL, October 25-26, 2003

Member, Workshop Planning Committee, *Environmental Factors in Autoimmune Diseases*, National Institute of Environmental Health Sciences, Durham, NC, February 4-5, 2003.

Co-organizer, 2nd International Myositis Assessment and Clinical Studies Workshop, *Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis*, NIH Office of Rare Diseases, NIAMS, NINDS, NIEHS funded meeting, New Orleans, LA, October 22-23, 2002

Co-organizer and moderator, 1st International Myositis Assessment and Clinical Studies Workshop, *Defining Improvement in Adult and Juvenile Myositis*, NIH Office of Rare Diseases, NIAMS, NINDS, and NIEHS funded meeting, San Francisco, CA, November 9th-10th, 2001

Organizer and moderator, *Approaches for Studying Possible Associations between Vaccinations and Rheumatic Disorders*, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, Philadelphia, PA, October 20, 2000

Co-organizer and co-moderator, *NIH Workshop on Basic and Clinical Research in Inflammatory Myopathy*, NIAMS-sponsored meeting, Bethesda, MD, April 5-6, 2000

Organizer and moderator, *Defining The Environmental Causes for Autoimmune Diseases*, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, Boston, MA, November 14, 1999

Organizer and moderator, *Drug-Associated Rheumatic Diseases*, American College of Rheumatology Environmentally Associated Rheumatic Disease Study Group Session, San Diego, CA, November 19, 1998.

Co-Organizer and moderator, Biologic Agents for Autoimmune Diseases IV, Washington, DC, March 1995

Co-Organizer and moderator, Immunology Session, FASEB meeting, Boston, MA. August, 1993

SELECTED EDITORIAL ACTIVITIES

Editorial Board, *The Open Rheumatology Journal*, Bentham Science Publishers Ltd., 2007 - present

Section Editor, *Current Opinion in Rheumatology*, 1995-8

Section Editor, *Rheumatic Disease Clinics North America*, 2001-2002

Co-Editor, *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, The Myositis Association, Washington, 2007.

AD HOC REVIEWER FOR JOURNALS (SELECTED RECENT EXAMPLES)

Annals of Internal Medicine, Arthritis and Rheumatism, Arthritis Care and Research, Environmental Health Insights, Journal of Clinical Rheumatology, Journal of Immunology, Journal of Rheumatology, Journal of Clinical Investigation, Journal of the National Cancer Institute, Lupus, Nature Medicine, Nucleic Acids Research, Rheumatology

SELECTED INVITED LECTURES

The Myositis Association Annual Meeting, Denver, CO, *The Environment and Autoimmune diseases – Where we stand in 2008; Myositis Research Highlights – What have we learned in the last 15 years.* September, 2008

The 15th Pediatric Rheumatology European Society Congress, London, UK, *Dissecting Genotype-Phenotype interactions in the Pathogenesis of Adult and Juvenile Myositis*, September, 2008

New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, September, 2008

NIEHS Public Interest Liaison Group Meeting, Washington, DC, *NIEHS Translational Research in the Environment and Autoimmune Diseases*, September, 2008

The XV PANLAR Congress, Guatemala City, Guatemala, *New Insights into the Pathogenesis and Management of Myositis*, August, 2008

Saint Louis University Medical Center Grand Rounds, *Deconstructing Myositis – What we know, what we think we know and what we need to know*, St. Louis, MO, May 2008

The Hospital for Special Surgery Grand Rounds, *Myositis Syndromes 2008 – Pearls, Myths and Realities*, New York, NY, April 2008

The 10th International Workshop on Autoantibodies and Autoimmunity, Guadalajara, Mexico, *Environmental Aspects of Autoimmunity*, March, 2008

Cure Juvenile Myositis Meeting, Washington, DC, *Genetics of Myositis – Current Status and New Opportunities*, October, 2007

New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, September, 2007

MYOPAIN 2007, Washington, DC, *Disorders of Muscle Inflammation – Pathogenic Insights from Environmental and Epidemiologic Studies*, August, 2007

Puerto Rican Rheumatologist's Association International Meeting, San Juan, Puerto Rico. *Dissecting Genotype-Phenotype Interactions in Myositis*, May, 2007

6th International Rheumatology Symposium, Yokohama, Japan, *Risk and Protective Factors for the Development of Myositis and Related Myopathies*, April, 2007

The Myositis Association Medical Advisory Board Annual Meeting, Washington, DC, *Research Progress and Opportunities in Polymyositis and Dermatomyositis*, January, 2007

American College of Rheumatology Annual Meeting, Washington, DC, ACR Clinical Symposium, *Developments in Myositis Response Criteria*, November, 2006

New York Rheumatology Board Review Course, New York, NY, *Update on Inflammatory and other Myopathies*, September, 2006

XIV Congress of the Pan-American League of Associations for Rheumatology (PANLAR) Lima, Peru, *Defining Risk Factors and Pathogenesises of Inflammatory Muscle Disease*, August, 2006

NIEHS Translation of Environmental Health Sciences Retreat, Chapel Hill, NC, *Intramural Clinical Research and Approaches to Enhancing Translational Studies*, June, 2005

The Annual European League of Associations for Rheumatism (EULAR) Congress of Rheumatology, Vienna, Austria, *Environmental Factors in Muscle Weakness*, June, 2005

Canadian Rheumatology Association National Meeting, Mont Tremblant, Quebec, The Dunlop-Dotteridge Plenary Lecture: *Close Encounters with the Myositis Syndromes*, March, 2005

NIEHS Division of Intramural Research Retreat, New Bern, NC, Mini Symposium *Environmental Aspects of Immune-Mediated Diseases*, October, 2004

NIAID Eosinophilia Myalgia Syndrome (EMS) Conference, Bethesda, MD. *Genetic risk factors for EMS*, October 2004

The Myositis Association Annual Conference, Las Vegas, NV, *Talking with your doctor about myositis; Myositis 101, What patients need to know and Myositis research update*, August, 2004

Myopain 2004, Annual Meeting of the International Myopain Society, Munich, Germany, Plenary lecture: *Clinical Symptoms & Therapies of Inflammatory Myopathies*, July, 2004

Clinical Immunology Society (CIS) Spring School in Systemic Autoimmune Diseases Meeting, Santa Fe, New Mexico, *Environmental and Genetic Aspects of Autoimmune Diseases: The Case for Elemental Disorders*, March, 2004

American College of Rheumatology Annual Meeting, Orlando, FL, *Meet the expert session on myositis and myopathies*; October, 2003

The Myositis Association Annual Conference, Houston, TX, *Translational research on myositis, from bench to bedside*, October, 2003

NIEHS Public Interest Liaison Group Meeting, New York, NY, *Autoimmune Disorders and Environmental Factors*, September, 2003

The UK Myositis Support Group Annual Meeting, Birmingham, UK, *Genetic and environmental risk factors for myopathies*, June 2003

Frontiers of Rheumatology - 21st Annual Carl M. Pearson Memorial Symposium, Huntington Beach, CA, *Differential Diagnosis of Muscle Disease: How Useful are Genetic Markers, Myositis Antibodies and Imaging Studies?* and *Optimizing the Benefit/Risk Ratio in the Management of Inflammatory Myopathies*, May, 2003

The Henry Kunkel Society 11th Annual Meeting, New York, NY, Plenary Lecture: *Global Surface Ultraviolet Radiation Intensity May Modulate the Clinical and Immunologic Expression of Autoimmune Muscle Disease*, April, 2003

The Royal Society of Medicine Kovacs Lectureship, London, UK, *Myositis: Aetiology and management*, March, 2003

NIEHS Conference on Environmental Factors in Autoimmune Disease, Durham, NC, *Gene-Environment Interactions in Autoimmune Diseases*, February, 2003

Mexican Society of Rheumatology Meeting, Nuevo Leon, Mexico, Plenary talk: *News and Views on Managing Polymyositis and Dermatomyositis*, February, 2003

American College of Rheumatology Annual Meeting, New Orleans, LA, *Meet the expert session on myositis and myopathies*, and Environmentally Associated Rheumatic Diseases Study Group Session, *Approaches to Evaluating Myopathies in Patients on Lipid-lowering Agents*, October, 2002

The Myositis Association of America Annual Conference, Atlanta, GA, *How we diagnose Myositis; and Myositis overlap syndromes*, September, 2002

Michigan Rheumatism Society Bi-Annual Meeting, Ann Arbor, MI, Special lecture – *Inflammatory myopathies through the looking glass of the myositis-specific autoantibodies*, June, 2002

University College, 2nd International Myositis Workshop, London, UK, *Approaches to assessing disease activity and damage in myositis*, May, 2002

The International Myopain Society, Scientific Interdisciplinary Working Group Annual Meeting, Munich, Germany, Plenary session: *News and views on inflammatory myopathies*, May, 2002

American College of Rheumatology Annual Meeting, San Francisco, CA, *Meet the expert session on myositis and myopathies*, November, 2001.

The Myositis Association of America Annual Conference, San Diego, CA, *New Directions in Myositis Research*, October, 2001

University of Pittsburgh School of Medicine, Department of Medicine Grand Rounds, Pittsburgh, PA. *Update on clinical presentation, diagnosis, pathogenesis and management of myositis*, March, 2001

WHO Exploratory Meeting of Epidemiology of Occupational and Environmental Factors Associated with Autoimmunity, Bilthoven, the Netherlands, *Epidemiologic Studies of Autoimmune Disease and the Environment*, May, 2000

UPCOMING INVITED LECTURES

University of North Carolina Grand Rounds, *New Developments in the Diagnosis, Assessment and Therapy of Myositis*, Chapel Hill, NC, November, 2008

AUTOCURE Annual Meeting, Prague, Czech Republic. *Genetic risk and protective factors for the idiopathic inflammatory myopathies*, December, 2008

BIBLIOGRAPHY

Peer-Reviewed Research Publications

1. Ilan, J, Pierce DR, **Miller, FW**. Influence of 9-beta-d-arabinofuranosyladenine on total protein synthesis and on differential gene expression of unique proteins in the rodent malarial parasite *Plasmodium berghei*. *Proc Natl Acad Sci U.S.A.* 1977; 74(8):3386-90.
2. **Miller, FW**, Ilan, J. The ribosomes of *Plasmodium berghei*: isolation and ribosomal ribonucleic acid analysis. *Parasitology.* 1978; 77(3):345-65.
3. Chawla, RK, **Miller, FW**, Lawson DH, Nixon DW. Urinary cancer-related protein EDC1 and serum inter-alpha trypsin inhibitor in breast cancer. *Tumour Biol.* 1984; 5(6):351-63.
4. Chawla, RK, Rausch, DJ, **Miller, FW**, Vogler WR, Lawson DH. Abnormal Profile of Serum Proteinase Inhibitors in Cancer Patients. *Cancer Res.* 1984; 44(6):2718-23.
5. **Miller, FW**, Ilan J. Evidence for major differences in ribosomal subunit proteins from *Plasmodium berghei* and rat liver. *Mol Biochem Parasitol.* 1984; 12(3):249-60.
6. Biswas, T, **Miller, FW**, Twitty, SA, Plotz, PH. An efficient method for enrichment of histidyl-tRNA synthetase (Jo-1 antigen) from HeLa cells. *J Immunol Methods.* 1987; 98(2):235-41.
7. Biswas, T, **Miller, FW**, Takagaki, Y, Plotz, PH. An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. *J Immunol Methods.* 1987; 98(2):243-8.
8. **Miller, FW**, Love, LA, Biswas, T, McClintock, PR, Notkins, AL, Plotz, PH. Viral and host genetic factors influence Encephalomyocarditis virus-induced polymyositis in adult mice. *Arthritis Rheum.* 1987; 30(5):549-56.
9. **Miller, FW**, Santero, TJ, Papadopoulos, NM. Idiopathic anasarca associated with oligoclonal gammopathy in systemic lupus erythematosus. *J Rheumatol.* 1987; 14(4):842-3.
10. **Miller, FW**, Moore, GF, Weintraub, BD, Steinberg, AD. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus. *Arthritis Rheum.* 1987; 30(10):1124-31.
11. Biswas, T, **Miller, FW**, Plotz, PH. Stimulation and partial stabilization of human histidyl-tRNA synthetase by hemoglobin. *FEBS Lett.* 1988; 229(1):203-5.
12. Allaway, GP, Srinivasappa J, Miller, **FW**, Prabhaker, BS, Notkins, AL. Spontaneously proliferating human B lymphocytes make autoantibodies. *J. Infectious Dis.* 1988; 157:968-972.
13. Cronin, ME, Love, LA, **Miller, FW**, McClintock, PR, Plotz, PH. The natural history of Encephalomyocarditis virus-induced myositis and myocarditis in mice. Viral persistence demonstrated by in situ hybridization. *J Exp Med.* 1988; 168(5):1639-48.
14. Cronin, ME, **Miller, FW**, Hicks, JE, Dalakas, M, Plotz, PH. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. *J Rheumatol.* 1989; 16(9):1225-8.
15. Kalovidouris, AE, **Miller, FW**, Lawley, TJ. Polymyositis/dermatomyositis associated with dermatitis herpetiformis. *Arthritis Rheum.* 1989; 32(9):1179-81.
16. Ramsden, DA, Chen, J, **Miller, FW**, Misener, V, Bernstein, RM, Siminovitch, KA, Tsui, FW. epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. analysis of the myositis-associated anti-Jo-1 autoimmune response. *J Immunol.* 1989; 143(7): 2267-72.
17. Recker, DP, Minor, JR, **Miller, FW**. Successful prevention of an anaphylactoid reaction to high-dose methotrexate. *DICP.* 1989; 23(12):1032.

18. **Miller, FW**, Twitty, SA, Biswas, T, Plotz, PH. Origin and regulation of a disease-specific autoantibody response. antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. *J Clin Invest.* 1990; 85(2):468-75.
19. **Miller, FW**, Love, LA, Barbieri, SA, Balow, JE, Plotz, PH. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. *Clin Exp Immunol.* 1990; 81(3):373-9.
20. Targoff, IN, Johnson, AE, **Miller, FW**. Antibody to signal recognition particle in polymyositis. *Arthritis Rheum.* 1990; 33(9):1361-70.
21. **Miller, FW**, Waite, KA, Biswas, T, Plotz, PH. The Role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. *Proc Natl Acad Sci U.S.A.* 1990; 87(24):9933-7.
22. Baker, JR Jr, **Miller, FW**, Steinberg, AD, Burman, KD. Thyroid stimulating and thyrotropin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. *Thyroid.* 1991; 1(3):229-34.
23. Love, LA, Leff, RL, Fraser, DD, Targoff, IN, Dalakas, M, Plotz, PH, **Miller, FW**. A New Approach to the classification of idiopathic inflammatory myopathy: myositis-specific auto-antibodies define useful homogeneous patient groups. *Medicine*, Baltimore, 1991; 70(6):360-74.
24. Fraser, DD, Frank, JA, Dalakas, M, **Miller, FW**, Hicks, JE, Plotz, P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. *J Rheumatol.* 1991; 18(11):1693-1700.
25. Leff, RL, Burgess, SH, **Miller, FW**, Love, LA, Targoff, IN, Dalakas, MC, Joffe, MM, Plotz, PH. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle auto-antibodies. *Arthritis Rheum.* 1991; 34(11):1391-6.
26. Leff, RL, Love, LA, **Miller, FW**, Greenberg, SJ, Klein, EA, Dalakas, MC, Plotz, PH. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. *Lancet.* 1992; 339(8803):1192-5.
27. **Miller, FW**, Leitman, SF, Cronin, ME, Hicks, JE, Leff, RL, Wesley, R, Fraser, DD, Dalakas, M, Plotz, PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *N Engl J Med.* 1992; 326(21):1380-4.
28. Fraser, DD, Kong, LI, **Miller, FW**. Molecular detection of persistent *Borrelia burgdorferi* in a man with dermatomyositis. *Clin Exp Rheumatol.* 1992; 10(4):387-90.
29. Targoff, IN, Trieu, EP, Plotz, PH, **Miller, FW**. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. *Arthritis Rheum.* 1992; 35(7):821-30.
30. Raben, N, Sherman, J, **Miller, FW**, Mena, H, Plotz, PH. A 5' splice junction mutation leading to exon deletion in an ashkenazic jewish Family with Phosphofructokinase Deficiency. *J.Biol.Chem.* 1993; 268:4963-4967
31. Joffe, MM, Love, LA, Leff, RL, Fraser, DD, Targoff, IN, Hicks, JE, Plotz, PH, **Miller, FW**. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. *Am J Med.* 1993; 94(4):379-87.
32. Targoff, IN, Trieu, EP, **Miller, FW**. Reaction of anti-OJ auto-antibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. *J Clin Invest.* 1993; 91(6):2556-64.

33. Leff, RL, **Miller, FW**, Hicks, J, Fraser, DD, Plotz, PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. *Medicine*, Baltimore, 1993; 72(4):225-35.
34. Hicks, JE, **Miller, FW**, Plotz, PH, Chen, TE, Gerber, L. Isometric exercise increases strength and does not produce sustained creatine kinase increases in a patient with polymyositis. *J.Rheum.* 1993; 20:1399-1401.
35. O'Hanlon, TP, Dalakas, MC, Plotz, PH, **Miller, FW**. Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *J Immunol.* 1994; 152(5):2569-76.
36. O'Hanlon, TP, Dalakas, MC, Plotz, PH, **Miller, FW**. The alpha beta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. *J Autoimmun.* 1994; 7(3):321-33.
37. Potter, M, Morrison, S, Wiener, F, Zhang, XK, **Miller, FW**. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. *J Natl Cancer Inst.* 1994; 86(14):1058-65.
38. Rider, LG, **Miller, FW**, Targoff, IN, Sherry, DD, Samayoa, E, Lindahl, M, Wener, MH, Pachman, LM, Plotz, PH. A broadened spectrum of juvenile myositis. myositis-specific auto-antibodies in children. *Arthritis Rheum.* 1994; 37(10):1534-8.
39. Boerkoel, CF, Exelbert, R, Nicastrì, C, Nichols, RC, **Miller, FW**, Plotz, PH, Raben, N. Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II. *Am J Hum Genet.* 1995; 56(4):887-97.
40. O'Hanlon, TP, Raben, N, **Miller, FW**. A novel gene oriented in a head-to-head configuration with the human histidyl-tRNA synthetase (HRS) gene encodes an mRNA that predicts a polypeptide homologous to HRS. *Biochem Biophys Res Commun.* 1995; 2:556-66.
41. O'Hanlon, TP, Messersmith, WA, Dalakas, MC, Plotz, PH, **Miller, FW**. Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *Clin Exp Immunol.* 1995; 100(3):519-28.
42. O'Hanlon, TP, Dalakas, MC, Plotz, PH, **Miller, FW**. The alpha beta T-cell receptor repertoire in idiopathic inflammatory myopathies: distinct patterns of gene expression by muscle-infiltrating lymphocytes in different clinical and serologic groups. *Ann N Y Acad Sci.* 1995; 756:410-3.
43. Potter, M, Morrison, S, **Miller, FW**. Induction of plasmacytomas in genetically susceptible mice with silicone gels. *Current Topics Microbiol Immunol.* 1995; 194:83-91.
44. O'Hanlon, TP, Okada, S, Love, LA, Dick, G, Young, VL, **Miller, FW**. Immunohistopathology and T cell receptor gene expression in capsules surrounding silicone breast implants. *Curr Top Microbiol Immunol.* 1996; 210:237-42.
45. Rivest, C, **Miller, FW**, Love, LA, Turgeon, PP, Blier, C, Senecal, JL. Focal myositis presenting as pseudothrombophlebitis of the neck in a patient with mixed connective tissue disease. *Arthritis Rheum.* 1996; 39(7):1254-8.
46. Hausmanowa-Petrusewicz, I, Kowalska-Oledzka, E, **Miller, FW**, Jarzabek-Chorzelska, M, Targoff, IN, Blaszczyk-Kostanecka, M, Jablonska, S. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. *Arthritis Rheum.* 1997; 40(7):1257-66.

47. Rider, LG, Feldman, BM, Perez, MD, Rennebohm, RM, Lindsley, CB, Zemel, LS, Wallace, CA, Ballinger, SH, Bowyer, SL, Reed, AM, Passo, MH, Katona, IM, **Miller, FW**, Lachenbruch, PA. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group. *Arthritis Rheum.* 1997; 40(11):1976-83.
48. Villalba, L, Hicks, JE, Adams, EM, Sherman, JB, Gourley, MF, Leff, RL, Thornton, BC, Burgess, SH, Plotz, PH, **Miller, FW**. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. *Arthritis Rheum.* 1998; 41(3):392-9.
49. Ginn, LR, Lin, JP, Plotz, PH, Bale, SJ, Wilder, RL, Mbauya, A, **Miller, FW**. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. *Arthritis Rheum.* 1998; 41(3):400-5.
50. Rider, LG, Gurley, RC, Pandey, JP, Garcia de la Torre, I, Kalovidouris, AE, O'Hanlon, TP, Love, LA, Hennekam, RC, Baumbach, LL, Neville, HE, Garcia, CA, Klingman, J, Gibbs, M, Weisman, MH, Targoff, IN, **Miller, FW**. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheum.* 1998; 41(4):710-19.
51. Summers, RM, Brune, AM, Choyke, PL, Chow, CK, Patronas, NJ, **Miller, FW**, White, PH, Malley, JD, Rider, LG. Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery MR Imaging. *Radiology.* 1998; 209(1):191-6.
52. Rider, LG, Shamim, E, Okada, S, Pandey, JP, Targoff, IN, O'Hanlon, TP, Kim, HA, Lim, YS, Han, H, Song, YW, **Miller, FW**. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: A tale of two loci. *Arthritis Rheum.* 1999; 42(6):1285-90.
53. Abbondanzo, SL, Young, VL, Wei, MQ, **Miller, FW**. Silicone gel-filled breast and testicular implant capsules: A histologic and immunophenotypic study. *Mod Pathol.* 1999; 12(7):706-13.
54. Centeno, JA, Mullick, FG, Panos, RG, **Miller, FW**, Valenzuela-Espinoza, A. Laser-Raman microprobe identification of inclusions in capsules associated with silicone gel breast implants. *Mod Pathol.* 1999; 12(7):714-21.
55. Laskin, BL, Choyke, P, Keenan, GF, **Miller, FW**, Rider, LG. Novel gastrointestinal tract manifestations in juvenile dermatomyositis. *J Pediatr.* 1999; 135(3):371-4.
56. O'Hanlon, TP, Lawless, OJ, Katzin, WE, Feng, LJ, **Miller, FW**. Restricted and shared patterns of TCR beta-chain gene expression in silicone breast implant capsules and remote sites of tissue inflammation. *J Autoimmun.* 2000; 14(4):283-93.
57. Rider, LG, Artlett, CM, Foster, CB, Ahmed, A, Neeman, T, Chanock, SJ, Jimenez, SA, **Miller, FW**. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. *Clin Exp Immunol.* 2000; 121(1):47-52.
58. Kimball, AB, Summers, RM, Turner, M, Dugan, EM, Hicks, J, **Miller, FW**, Rider, LG. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy. *Arthritis Rheum.* 2000; 43(8):1866-73.
59. D'Cruz, D, Keser, G, Khamashta, MA, Direskeneli, H, Targoff, IN, **Miller, FW**, Hughes RVG. Anti-endothelial cell antibodies in inflammatory myopathies: distribution among clinical and serological groups and association with interstitial lung disease. *J.Rheum.* 2000; 27:161-164.

60. Artlett, CM, Ramos, R, Jiminez, SA, Patterson, K, **Miller, FW**, Rider, LG. Chimeric Cells of Maternal Origin in Juvenile idiopathic inflammatory myopathies. childhood myositis heterogeneity collaborative group. *Lancet*. 2000; 356(9248):2155-6.
61. Huber, AM, Hicks, JE, Lachenbruch, PA, Perez, MD, Zemel, LS, Rennebohm, RM, Wallace, CA, Lindsley, CB, Passo, MH, Ballinger, SH, Bowyer, SL, Reed, AM, White, PH, Katona, IM, **Miller, FW**, Rider, LG, Feldman BM; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the childhood health assessment questionnaire in the juvenile idiopathic myopathies. *J Rheumatol*. 2001; 28(5):1106-11.
62. Woodworth, TG, Furst, DE, Strand, V, Kempeni, J, Fenner, H, Lau, CS, **Miller, F**, Day, R, Lipani, J, Brooks, P. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: Towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. *J.Rheum*. 2001; 28: 1163-1169.
63. **Miller, FW**, Rider, LG, Chung, YL, Cooper, R, Danko, K, Farewell, V, Lundberg, I, Morrison, C, Oakley, L, Oakley, I, Pilkington, C, Vencovsky, J, Vincent, K, Scott, DL, Isenberg, DA; International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology*, Oxford, 2001; 40(11):1262-73.
64. Artlett, CM, **Miller FW**, Rider, LG; Childhood Myositis Heterogeneity Collaborative Study Group. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. *Rheumatology*, Oxford, 2001; 40(11):1279-84.
65. O'Hanlon, TP, **Miller, FW**. Genomic Organization, Transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL). *Biochem Biophys Res Commun*. 2002; 294(3):609-14.
66. Shamim, EA, Rider, LG, Pandey, JP, O'Hanlon, TP, Jara, LJ, Samayoa, EA, Burgos-Vargas, R, Vazquez-Mellado, J, Alcocer-Varela, J, Salazar-Paramo, M, Kutzbach, AG, Malley JD, Targoff IN, Garcia-De la Torre I, **Miller FW**. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: Ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum*. 2002; 46(7):1885-93.
67. Rider, LG, Schiffenbauer, AS, Zito, M, Lim, KL, Ahmed, A, Zemel, LS, Rennebohm, RM, Passo, MH, Summers, RM, Hicks, JE, Lachenbruch, PA, Heyes, MP, **Miller, FW**; Juvenile Dermatomyositis Disease Activity Collaboration Study Group. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *Clinical Chemistry*. 2002; 48(10):1681-8.
68. Okada, S, Weatherhead, E, Targoff, IN, Wesley, R, **Miller, FW**; International Myositis Collaborative Study Group. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. *Arthritis Rheum*. 2003; 48(8):2285-93.
69. Artlett, CM, O'Hanlon, TP, Lopez, AM, Song, YW, **Miller, FW**, Rider, LG. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. *Arthritis Rheum*. 2003; 48(9):2567-72.

70. Huber, AM, Feldman, BM, Rennebohm, RM, Hicks, JE, Lindsley, CB, Perez, MD, Zemel, LS, Wallace, CA, Ballinger, SH, Passo, MH, Reed, AM, Summers, RM, White, PH, Katona, IM, **Miller, FW**, Lachenbruch, PA, Rider, LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2004; 50(5):1595-603.
71. Isenberg, DA, Allen, E, Farewell, V, Ehrenstien, MR, Hanna, MG, Lundberg, IE, Oddis, C, Pilkington, C, Plotz, P, Scott, D, Vencovsky, J, Cooper R, Rider, L, **Miller, F**. International Consensus Outcome Measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology*, Oxford, 2004; 43(1): 49-54.
72. Chanock, SJ, Foster, CB, **Miller, FW**, O'Hanlon, TP. HLA-A, -B, -Cw, -DQA1 and DRB1 in a Caucasian population from Bethesda, USA. *Human Immunology* 2004; 65:121-1223.
73. Chanock, SJ, Foster, CB, **Miller, FW**, O'Hanlon, TP. HLA-A, -B, -Cw, -DQA1 AND DRB1 in an African-American population in Bethesda, USA. *Human Immunology*, 2004; 65:1223-1235.
74. Rennebohm, RM, Jones, K, Huber, AM, Ballinger, SH, Bowyer, SL, Feldman, BM, Hicks, J, Katona, IM, Lindsley, CB, **Miller, FW**, Passo, MH, Perez, MD, Reed, AM, Wallace, CA, White, PH, Zemel, LS, Lachenbruch, PA, Hayes, JR, Rider, LG; Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale. *Arthritis Rheum.* 2004; 51(3):365-70.
75. Rider, LG, Giannini, EH, Brunner, HI, Ruperto, N, James-Newton, L, Reed, AM, Lachenbruch, PA, **Miller, FW**; International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. *Arthritis Rheum.* 2004; 50(6):2281-90.
76. O'Hanlon, T, Koneru, B, Bayat, E, Love, L, Targoff, I, Malley, J, Malley, K, **Miller, F**; Environmental Myositis Study Group. Immunogenetic differences between Caucasian women with and those without silicone implants in whom myositis develops. *Arthritis Rheum.* 2004; 50(11):3646-50.
77. O'Hanlon, TP, Mercatante-Carrick, D, Arnett, FC, Reveille, J, Carrington, M, Oddis, CV, Morel, P, Malley, JD, Malley, K, Dreyfuss, J, Shamim, E, Rider, LG, Chanock, SJ, Foster, C, Bunch, T, Plotz, PH, Love, LA, **Miller, FW**. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -C, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. *Medicine (Baltimore)* 2005;84(6):338-49.
78. Chung, Y-L, Rider, LG, Bell, JD, Summers, RM, Zemel, LS, Rennebohm, RM, Passo, MH, Hicks, J, **Miller, FW**, Scott, DL, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005;53(4):565-70.
79. Sarkar, K, Weinberg CR, Oddis, CV, Medsger, TA, Plotz, PH, Reveille, JD, Arnett, FC, Targoff, IN, Genth, E, Love, LA, **Miller, FW**. Seasonal influence in the onset of idiopathic inflammatory myopathies. *Arthritis Rheum.* 2005;52(8):2433-8.
80. Römisch, K, **Miller, FW**, Dobberstein, B and High, S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages, *Arthritis Research & Therapy* 2006;8(2):R39.

81. Nagaraju K, Rider LG, Fan C, Chen YW, Megan M, Rawat R, Patterson K, Grundtman C, **Miller FW**, Plotz PH, Hoffman EP, Lundberg I. Endothelial cell activation and neovascularization are prominent in dermatomyositis. *J Autoimmune Dis.* 2006;20(1):2-8.
82. O'Hanlon, TP, Mercatante-Carrick, D, Targoff, IN, Arnett, FC, Reveille, J, Carrington, M, Gao, X, Oddis, CV, Morel, P, Malley, JD, Malley, K, Shamim, E, Rider, LG, Chanock, SJ, Foster, C, Bunch, T, Blackshear, PJ, Plotz, PH, Love, LA, **Miller, FW**. Immunogenetic Risk and Protective Factors for the Idiopathic Inflammatory Myopathies: Distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 Allelic Profiles Distinguish European American Patients With Different Myositis Autoantibodies. *Medicine (Baltimore)*, 2006;85(2):111-127.
83. Targoff, IN, Mamyrova, G, Trieu, E, Perurena, O, Koneru, B, O'Hanlon, YP, **Miller, FW***, Rider, LG*, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155 kd protein is associated with dermatomyositis. *Arthritis Rheum.* 2006; 54:3682-3689 *contributed equally
84. O'Hanlon, TP, Rider, LG, Mamyrova, G, Targoff, IN, Arnett, FC, Reveille, J, Carrington, M, Gao, X, Oddis, CV, Morel, P, Malley, JD, Malley, K, Shamim, E, Chanock, SJ, Foster, C, Bunch, T, Plotz, PH, Love, LA, **Miller, FW**. HLA Polymorphisms in African Americans with Idiopathic Inflammatory Myopathies: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies, *Arthritis Rheum.* 2006; 54:3670-3681.
85. Mamyrova G, O'Hanlon TP, Monroe J, Mercatante Carrick D, Malley J, Adams S, Reed AM, Shamim E, James Newton L, **Miller FW**, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasian patients, *Arthritis Rheum.* 2006; 54:3979-3987.
86. Mamyrova, G, Kleiner, D, Shaham, B, Cartwright, V, James-Newton, L, **Miller, FW**, Rider, L. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy and pneumatosis intestinalis, *Arthritis Rheum.* 2007; 57:881-884.
87. Vegosen, L, Weinberg, C, O'Hanlon, T, Targoff, I, Koneru, B, Mamyrova, G, **Miller, FW**, Rider, L and the Childhood Myositis Heterogeneity Study Group. Seasonal birth patterns suggest a role for perinatal environmental factors in the etiology of subgroups of myositis, *Arthritis Rheum.* 2007; 56:2729-2739.
88. Huber, AM, Dugan, EM, Lachenbruch PA, Feldman, BM, Lindsley, CB, Reed, SM, **Miller, FW** and Rider, LG. The Cutaneous Assessment Tool (CAT): Development and Reliability in Juvenile Idiopathic Inflammatory Myopathy, *Rheumatology*, 2007; 46:1606-1611.
89. Csako, G, Costello, R, Shamim, E, O'Hanlon T, Tran, A, Clauw, D, Williams, HJ and **Miller, FW**. Serum proteins and paraproteins in women with silicone implants and connective tissue disease, *Arthritis Research & Therapy*, 2007, 9:R95.
90. Huber AH, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, **Miller FW**, Rider LG, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis. *Arthritis Rheum.* 2008; 59:214-221.

91. Huber, AH, Lachenbruch, PA, Dugan, E, **Miller, FW**, Rider, L. Alternative scoring of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis: Results using abbreviated formats. *Arthritis Rheum.* 2008; 59:352-356.
92. Bingham, A, Mamyrova, G, Rother, KI, Oral, E, Cochran, E, Premkumar, A, Kleiner, D, James-Newton, L, Targoff, IN, Pandey, JP, Carrick, DM, Sebring, N, O'Hanlon, TP, Ruiz-Hidalgo, M, Turner, M, Gordon, LB, Laborda, J, Bauer, SR, Blackshear, PJ, Imundo, L, **Miller, FW**, Rider, LG, for the Childhood Myositis Heterogeneity Study Group. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. *Medicine (Baltimore)*, 2008; 87: 70-86.
93. O'Hanlon TP, Rider LG, Schiffenbauer A, Targoff IN, Malley K, Pandey JP, **Miller, FW**. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. *Arthritis Rheum*, 2008; 58: 3239-3246.
94. Ball, R, Shadomy, S, Meyer, A, Huber, B, Leffell, MS, Zachary, A, Belotto, M, Hilton, E, Bryant-Genevier, M, Schriefer, M, **Miller, FW**, Braun, MM. HLA-type and Immune Response to B. Burgdorferi Outer Surface Protein A in People Who Developed Arthritis after Lyme Vaccine. *Arthritis Rheum*, 2008 *in press*.
95. Mamyrova, G, O'Hanlon, TP, Sillers L, Malley K, James-Newton, L, Parks, CG, Cooper, GS, Pandey, JP, **Miller FW**, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group. Cytokine Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis *Arthritis Rheum*, 2008 *in press*.
96. Harris-Love, MO, Shrader, JA, Koziol, D, Pahlajani, N, Jain, M, Smith, M, Cintas, HL, McGarvey, CL, James-Newton, L, Pokrovnichka, A, Moini, R, Cabalar, I, Lovell, DJ, Wesley, R, Plotz, PH, **Miller, FW**, Hicks, JE, and Rider, LG. Distribution and Severity of Weakness Among Patients with Polymyositis, Dermatomyositis and Juvenile Dermatomyositis, *Rheumatology*, *in press*.
97. Burd, CJ, Kinyamu, HK, **Miller, FW** and Archer, TK. UV radiation regulates Mi-2 through protein translation and stability. *J Biol Chem.* 2008 Oct 15. [Epub ahead of print]

Submitted manuscripts

1. Okada, S, Kamb, ML, Pandey, JP, Philan, R, Love, LA, **Miller, FW**. Immunogenetic risk and protective factors for L-tryptophan associated eosinophilia-myalgia syndrome.
2. Lachenbruch, PA, **Miller, FW**, Rider, LG. On Determining the Effects of Therapy on Disease Damage in Non-randomized Studies with Multiple Treatments: A study of Juvenile Myositis
3. Coyle, K, Rother, KI, Weise, M, Ahmed, A, **Miller, FW**, Rider, LG. Metabolic Abnormalities Predictive of Cardiovascular Disease Are Frequent in Children with Myositis

4. Eidelman ,E, Boyde, A, Bushby, AJ, Howell , PG, Sun, J, **Miller, FW**, Robey, PG, Rider , LG. Microstructure and Mineral Composition of Dystrophic Calcification Associated with the Idiopathic Inflammatory Myopathies.

Invited Reviews, Letters, Books and Other Peer-reviewed Articles

1. **Miller, FW**, Santoro, TJ. Nifedipine in the treatment of migraine headache and amaurosis fugax in patients with systemic lupus erythematosus (letter). *N. Engl. J. Med.* 1984; 311(14):921.
2. **Miller, FW**, Baker, JR, Jr., Burman, KD, and Steinberg, AD. Thyroid-stimulating and thyrotropin binding-inhibiting immunoglobulins in patients with systemic lupus erythematosus. In *Clinical Immunology*, 1987; Elsevier Science Publishers, Amsterdam, Eds. W. Pryzanski, M. Seligman, 73-76.
3. **Miller, FW**, Love, LA. Prevention of predictable Raynaud's phenomenon with sublingual nifedipine (letter). *N. Engl. J. Med.* 1987; 317:1476.
4. Allaway, GP, Srinivasappa, J, **Miller, FW**, Prabahakar, BS, and Notkins, AL. Autoantibody production by human B lymphocytes which spontaneously proliferate. In *Epstein-Barr Virus and Human Diseases*, 1987; The Humana Press, P. 287-291. Eds. PH Levine.
5. Cronin, ME, **Miller, FW** and Plotz, PH. Polymyositis and Dermatomyositis, Chapter 21, *Primer on the Rheumatic Diseases*, 1988; 9th Edition, Ed. HR Schumaker, Jr.
6. Cronin, ME, Plotz, PH, **Miller, FW**. Abnormalities of the immune system in the idiopathic inflammatory myopathies. *In Vivo*, 1988; 2:25-30.
7. Plotz, PH, **Miller, FW**. Animal models of polymyositis. *Mt.Sinai J. Med.* 1988, 55:501-505.
8. **Miller, FW**. Pathogenesis, pp. 150-153, and Conclusions, p. 155. In: Plotz, PH et al., Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. *Ann. Intern. Med.* 1989; 111:143-57.
9. Tsui FW, Bernstein RM., Mathews MB, **Miller FW**. Mapping the epitopes on Jo-1 (histidyl-tRNA synthetase). *Prog Leukocyte Biol* 1989; 9: 473–6.
10. **Miller, FW**. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. *Current Opinion Rheum.* 1991; 3:902-910.
11. **Miller, FW**, Leitman, SL, Plotz, PH. Plasma exchange in polymyositis and dermatomyositis. (letter) *New Engl. J. Med.* 1992; 327:1030-1.
12. Tsui, FWL, **Miller, FW**. Idiopathic Inflammatory Myopathies, Chapter 23 in *The Molecular Pathology of Autoimmunity*, 1993. Eds. C. Bona et al., Harwood Academic Publishers, Eds. CA Bona, K Siminovitch, AN Theofilopoulos, M Zanetti.
13. **Miller, FW**. Myositis-specific autoantibodies: Touchstones for understanding the inflammatory myopathies. *JAMA*, 1993; 260:1846-1849.
14. **Miller, FW**. Seasonal, geographic, clinical and immunogenetic associations of the myositis-specific autoantibodies. *Systeme Nerveux, Muscles et Maladies Systemiques*, 1993; Expansion Scientifique Francaise, Paris, Eds. G Serratrice.
15. Plotz, PH, Leff, RL, **Miller, FW**. Inflammatory and Metabolic Myopathies. Chapter 14, 127-131. In *Primer on the Rheumatic Diseases*, 1993; 10th Edition, Ed. HR Schumacher Jr.

16. Love, LA, **Miller, FW**. Non-Infectious environmental agents associated with myopathy. *Current Opinion Rheum* 1993; 5:712-718.
17. Plotz, PH, **Miller, FW**. Etiology and Pathogenesis of Inflammatory Muscle Disease. Chapter 13, 13.1-13.10. In *Rheumatology*, 1994; Mosby, Gower Medical Publishing, London, Eds. JH Klippel, DA Dieppe.
18. **Miller, FW**. Classification and prognosis of inflammatory muscle disease. in inflammatory muscle disease, *Rheumatic Disease Clinics of North America*, 1994; 20:811-826.
19. Rider, LG, **Miller, FW**. New perspectives on the idiopathic inflammatory myopathies of childhood. *Current Opinion Rheum* 1994; 6:575-582.
20. Pachman, LM, **Miller, FW**. Idiopathic Inflammatory Myopathies: Dermatomyositis, Polymyositis and Related Disorders. Chapter 41, pp 791-804 in *Samter's Immunologic Diseases*, 1995; Little, Brown and Company, Boston, Eds. M Frank; K Austen, H, Claman, E. Unanue
21. Rider, LG, **Miller, FW**. Laboratory Evaluation of the Inflammatory Myopathies. *Clinical and Diagnostic Laboratory Immunology* 1995; 2:1-9.
22. Plotz, PH Rider, LG, Targoff, IN, Raben, N, O'Hanlon, TP, **Miller, FW**. Myositis: Immunologic contributions to understanding cause, pathogenesis and therapy. *Annals Int. Med.* 1995; 122:715-724.
23. **Miller, FW**. Genetics of autoimmune diseases. *Experimental and Clinical Immunogenetics*, 1995; 12:182-190.
24. O'Hanlon, TP, **Miller, FW**. T cell-mediated immune mechanisms in myositis. *Curr. Opin. Rheum*, 1995; 7:503-509.
25. **Miller, FW**. Myositis - Patient Information Pamphlet. Arthritis Foundation, Atlanta, pp. 1-8, 1995.
26. Love, LA , **Miller, FW**. (1995) Understanding the idiopathic inflammatory myopathies. *Contemporary Internal Medicine*. 7:29-43
27. **Miller, FW**, Sawyer, WR. What Causes Myositis? National Myositis Association Newsletter 16:2-3, 1996.
28. **Miller, FW**. Anti-Signal Recognition Particle Autoantibodies. In *Autoantibodies*, pp. 735-740, 1996; Elsevier Sciences BV, Amsterdam, Eds. JB Peters, Y Shoenfeld.
29. **Miller, FW**. Intravenous Immunoglobulin In Polymyositis/Dermatomyositis. In Proceedings: Early Decisions in DMARD Development IV. Biologic Agents in Autoimmune Disease, pp 205-212, Arthritis Foundation, 1996; Atlanta, Ed. V. Strand.
30. **Miller, FW**. Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Conditions. Chapter 73 in *Arthritis and Allied Conditions: A Textbook of Rheumatology*, pp. 1407-1432, 1996; Williams & Wilkins, Baltimore, Ed. W Koopman.
31. **Miller, FW**. Commentary on correlation of anti-synthetase levels with disease course in a patient with interstitial lung disease and elevation of muscle Enzymes. *J. Clin. Rheum*. 1996.
32. **Miller, FW**. Editorial overview: Myositis and myopathies. *Curr. Opinion of Rheumatology*, 1996; 8:491-494.
33. Epstein, S, **Miller, FW**. What's in a Name? (letter). *The Scientist*, 1997; 11:9.
34. **Miller, FW**, Urnovitz, H. Genetic Factors Affecting Development of Autoimmunity. pp. 35-37. *Institute of Medicine Vaccine Safety Forum*. National Academy Press, 1997; Washington, DC.

35. Rider, LG, **Miller, FW**. Classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheumatic Disease Clinics of North America*, 1997; 23:619-655.
36. **Miller, FW**. Editorial overview: Myositis and myopathies. *Curr. Opinion of Rheumatology*, 1997; 9:471-474.
37. Targoff, IN, **Miller, FW**, Medsger, TA, Oddis, CV. Classification criteria for the idiopathic inflammatory myopathies. *Curr. Opinion of Rheumatology*, 1997; 9:527-536.
38. Plotz, PH, **Miller, FW**. Etiology and pathogenesis of inflammatory muscle disease. Chapter 14, 14.1-14.10. In *Rheumatology*, 1997; Second Edition, Mosby, Gower Medical Publishing, London, Eds. JH Klippel and PA Dieppe.
39. **Miller, FW**. Editorial overview: Myositis and myopathies. *Curr. Opinion of Rheumatology*, 1998; 10:499-503
40. **Miller, FW**. Genetics of environmentally-associated rheumatic diseases. In *Rheumatic Diseases and the Environment*, 1999; Chapter 4, p 33-40, Chapman & Hall Medical Publishers, New York, Eds. L Kaufman and J Varga.
41. Cooper, GS, **Miller, FW**, and Pandey, JP. The role of genetic factors in autoimmune diseases: implications for environmental research. *Environmental Health Perspectives*, 1999; 107 (Suppl 5):693-700
42. **Miller, FW**, Hess, EV, Clauw, DW, Hertzman, PA, Pincus, T, Silver, RM, Mayes, MD, Varga, J, Medsger, TA, Love, LA. Approaches for identifying and defining environmentally associated rheumatic disorders. *Arthritis Rheum* 2000; 43:243-249
43. Shamim, EA and **Miller, FW**. Familial autoimmunity and the idiopathic inflammatory myopathies. *Current Rheumatology Reports*, 2000; 2:201-211.
44. Rider, LA, **Miller, FW**. Idiopathic inflammatory muscle disease: Clinical Aspects. *Bailliere's Best Practice and Research in Clinical Rheumatology* 2000; 14:37-54
45. **Miller, FW**, Wortmann, RL, Robbins, L. Myositis - Patient Information Pamphlet. Arthritis Foundation, Atlanta, 2000.
46. Shamim, EA, Rider, LG, **Miller, FW**. Update on the genetics of the idiopathic inflammatory myopathies. *Curr. Opinion of Rheumatology*, 2000; 12: 482-491
47. Plotz, PH, **Miller, FW**, Hoffman, E, Casciola-Rosen, L, Rosen, A. Workshop on Inflammatory Myopathy Bethesda, 5-6 April 2000; *Neuromuscul Disord* 2001; 11:93-95
48. **Miller, FW**. Inflammatory myopathies: Polymyositis, dermatomyositis, and related conditions. In *Arthritis and Allied Conditions, A Textbook of Rheumatology*, 2000, 14th Edition, Chapter 78, 1562-1589 (volume 2), Lippincott, Williams, and Wilkins, Philadelphia, Ed. W. Koopman.
49. Richter-Reichhelm, H, Stahlmann, R, Smith, E, Van Loveren, H, Altoff, J, Bass, R, Corsini, E, Dayan, A, Dean, JH, Descotes, J, Emmendorffer, A, Eppler, R, Hall, AJ, Herrman, JL, Lovik, M, Luster, MI, **Miller, FW**, Riecke, K, Schoning, G, Schulte, A, Smialowicz, RJ, Ulrich, P, Vohr, HW, Vos, JG, White, KL. Approaches to risk assessment of immunotoxic effects of chemicals. *Toxicology* 2001; 161:213-228.
50. Pachman, LM, **Miller, FW**. Idiopathic inflammatory myopathies: Dermatomyositis, polymyositis and related disorders. In *Samter's Immunologic Diseases*, 6th Ed, 2001, Chapter 41, pp 791-804, Little, Brown and Company, Boston, Eds. K F Austen, MM Frank, JP Atkinson, H Cantor.

51. Plotz, PH, **Miller, FW**. Myositis classics: An historical perspective at the millennium. In *Classic Papers in Rheumatology*, 2001, Martin Dunitz, London. Chapter 15, Pages 222-235, Ed. P Dieppe et al.
52. Cooper, GS, **Miller, FW**, Germolec, DR. Occupational exposures and autoimmune diseases. *International Immunopharmacology*, 2002, 2: 303-313.
53. **Miller FW**, Editor. Idiopathic Inflammatory Myopathies, *Rheumatic Disease Clinics North America*, 2002; 28 (4).
54. **Miller, FW**. Preface to idiopathic inflammatory myopathies, *Rheumatic Disease Clinics North America* 28 (4): XI-XIII, 2002, Ed. FW Miller.
55. **Miller, FW**. Myositis. In *Targeted Therapies in Rheumatology*. 2003, Martin Dunitz, London. Chapter 36, 603-620, Eds. JS Smolen and PE Lipsky.
56. Henderson, C, **Miller, FW**, Minor, M. Wortmann, RL. Myositis - Patient information pamphlet. Arthritis Foundation, 2003, Atlanta, pp. 1-7.
57. **Miller, FW**. Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Conditions. In *Clinical Primer of Rheumatology*. 2003, Chapter 15, 182-198, Lippincott, Williams, and Wilkins, Philadelphia, Eds. WJ Koopman, DW Boulware, GR Huedebert.
58. Rider, L, Giannini, E, Harris-Love, M, Joe, G, Isenberg, D, Pilkington, C, Lachenbruch, P, **Miller, FW**. Defining clinical improvement in adult and juvenile myositis. *J Rheumatol* 2003, 30: 603-17.
59. Nagaraju, K, Plotz, PH, **Miller, FW**. Etiology and pathogenesis of inflammatory muscle disease. Chapter 138, 1523-1535. In *Rheumatology*, Third Edition, 2003; Mosby, Elsevier Limited, London, Eds. MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman.
60. **Miller, FW**, Rider, LG, Plotz, PH, Isenberg, DA, Oddis, CV. Diagnostic criteria for polymyositis and dermatomyositis. *Lancet*. 2003; 362(9397):1762-3 (letter).
61. Rider, LG, Giannini, EH, Harris-Love, M, Joe, G, Isenberg, D, Pilkington, C, Lachenbruch, PA, **Miller, FW**; International Myositis Assessment and Clinical Studies Group. Defining clinical improvement in adult and juvenile myositis. *J Rheumatol*. 2003; 30(3):603-17.
62. **Miller, FW**. Polymyositis and Dermatomyositis, Chapter 283, 1680-1684, In *Cecil Textbook of Medicine*, 22nd Edition, 2004; Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
63. **Miller, FW**, Rider, LG, Plotz, PH, Rutkove, SB, Pestronk, A, Wortmann, RL, Lundberg, IE, Argov, Z, Isenberg, DA, Lacomis, D, Oddis, CV. Polymyositis: An overdiagnosed entity. *Neurology* 2004; 63:402 (letter).
64. Sarkar, K, **Miller, FW**. Possible roles and determinants of microchimerism in autoimmune and other disorders. *Autoimmun Rev*. 2004; 3:454-63.
65. **Miller, FW**. Myositis. Chapter 10, 187-201. In *The Year in Rheumatic Disorders*, 2004; Volume 4, Clinical Publishing, Oxford, Eds. R Madhok and H Capell.
66. Sarkar, K, **Miller, FW**. Autoantibodies as Predictive and Diagnostic Markers of Idiopathic Inflammatory Myopathies. *Autoimmunity*. 2004; 37(4):291-4.
67. Kerns, W, Schwartz, L, Blanchard, K, Burchiel, S, Essayan, D, Fung, E, R Johnson, R, Lawton, M, Loudon, C, MacGregor, J, **Miller, FW**, Nagarkatti, P, Robertson, D, Sistare, F, Snyder, P, Thomas, H, Wagner, B, Ward, A, Zhang, J (FDA Expert Working Group on Drug-Induced Vascular Injury). Drug-Induced Vascular Injury—A Quest for Biomarkers. *Toxicology and Applied Pharmacology*, 2004; 203(1): 62-87.

68. **Miller, F.W.** Clinical presentation and therapy of the idiopathic inflammatory myopathies. *Journal of Musculoskeletal Pain*, 2004; 12:85-91.
69. **Miller, FW.** Inflammatory Myopathies: Polymyositis, Dermatomyositis, and Related Conditions. In *Arthritis and Allied Conditions - A Textbook of Rheumatology*, 2005; 15th Edition, Chapter 75 (volume 2), 1593-1620. Lippincott Williams & Wilkins, Philadelphia, Eds. W Koopman, L Moreland.
70. Huber, AM, **Miller FW**, Rider, LG. Validation and clinical significance of the Childhood Myositis Assessment Scale – Reply. *Arthritis Rheum*, 2005; 52:368-369 (letter).
71. Oddis, CV, Rider, LG, Reed, AM, Ruperto, N, Brunner, H, Koneru, B, Feldman, BM, Giannini, EH, and **Miller, FW** for the International Myositis Assessment and Clinical Studies Group (IMACS). International consensus guidelines for therapeutic trials in the idiopathic inflammatory myopathies, *Arthritis Rheum.*, 2005; 52(9):2607-2615.
72. **Miller, FW.** Non-infectious Environmental Agents and Autoimmunity. Chapter 23. *The Autoimmune Diseases*, 2006; 297-308, Elsevier, Boston; 4th Edition, Eds. NR Rose, IR Mackay.
73. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, **Miller FW**, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. *Biol Blood Marrow Transplant*. 2006; 12(3):252-66.
74. **Miller, FW.** Is occupational exposure to mineral oil a risk factor for rheumatoid arthritis? *Nature Clinical Practice Rheumatology*, Practice Point Commentary, 2006; 2(3):131.
75. **Miller, FW.** How do we best define autoantibodies? *Ann Rheum Dis*, 2006; eLetter <http://ard.bmjournals.com/cgi/eletters/65/2/242#521>.
76. O’Hanlon TP and **Miller, F.W.** The Idiopathic Inflammatory Myopathies (IIM): HLA polymorphisms distinguish patients with different clinical phenotypes and myositis-specific autoantibodies, *ASHI Quarterly*, 2006; Fourth quarter: 98-100.
77. Cooper, GS and **Miller, FW.** Environmental influences on autoimmunity and autoimmune diseases. Chapter 25, In *Immunotoxicology and Immunopharmacology*, 2007; 437-454, CRC Press, New York, 3rd Edition, Eds. R Luebke et al.
78. Rider LG, L Pachman, **FW Miller**, Bollar H, Editors. *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; 1-466, The Myositis Association, Washington.
79. Rider LG, **FW Miller.** What Is Juvenile Myositis?, Chapter 1, In *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007: 9-22, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
80. **Miller, FW**, Lovell, D. New Therapies on the Horizon. Chapter 15, In *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007; 207-216, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.

81. Lovell, D, **Miller, FW**. How We Learn About Juvenile Myositis? Chapter 39, In *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, 2007: 423-434, The Myositis Association, Washington, Eds. LG Rider, L Pachman, FW Miller, H Bollar.
82. Gourley, M and **Miller, FW**. Mechanisms of Disease: Environmental Factors in the Pathogenesis of Rheumatic Disease. *Nature Clinical Practice Rheumatology* 2007; 3:172-180
83. Lachenbruch, PA, **Miller, FW**, Lisa G. Rider. Developing international consensus on measures of improvement for myositis. *Statistical Methods in Medical Research*, 2007; 16:51-64
84. **Miller, FW**. Polymyositis and Dermatomyositis, Chapter 290, In *Cecil Textbook of Medicine*, 2007, 23rd Edition; 2045-2049, Saunders, Philadelphia, Eds. L Goldman, D Ausiello.
85. **Miller, FW**. Myositis, Chapter 38, In *Contemporary Targeted Therapies in Rheumatology*, 2007, 467-484, Informa Healthcare, London, Eds. JS Smolen and PE Lipsky.
86. Rider, LG and **Miller, FW**. Idiopathic Inflammatory Myopathies, Pathology and Pathogenesis, Chapter 18B, *Primer on the Rheumatic Diseases*, Thirteenth Edition, 2007, 368-374, Springer, Arthritis Foundation, New York, Ed. J. Klippel et al.
87. **Miller, F.W.** and Cooper, GS. Environmental aspects of lupus, Chapter 3, *Dubois' Lupus Erythematosus*. 2007; 21-33, 7th Edition; Lippincott Williams and Wilkins, Philadelphia, Eds. D Wallace, B Hahn.
88. Rider LG, Lachenbruch P, Isenberg DA, **Miller FW**. Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: Comment on the article by Ruperto et al. *Arthritis Rheum*. 2008;59:1197-1198 (letter).
89. **Miller, FW**. Idiopathic Inflammatory Myopathies. Chapter 15.6, In *American College of Physicians ACP Medicine*, WebMD Professional Publishing, New York, Ed. S Ruddy, *in press*.
90. **Miller, FW**. Classification of the idiopathic inflammatory myopathies, Chapter 2 in *The Inflammatory Myopathies*, Springer, New York, Ed. L. Kagen, *in press*.